TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
SOUTH SAN FRANCISCO, Calif., July 26, 2017 -- Five Prime Therapeutics, Inc. (NASDAQ:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, will report its second quarter 2017 financial results on Tuesday, August 8, 2017, after the U.S. financial markets close. Five Prime will host a conference call and live audio webcast on Tuesday, August 8, 2017, at 4:30 p.m. (ET)/1:30 p.m. (PT) to discuss the company's financial results and provide a general business update.
The live audio webcast may be accessed through the "Events & Presentations" page in the "Investors" section of the company's website at www.fiveprime.com. Alternatively, participants may dial (877) 878-2269 (domestic) or (253) 237-1188 (international) and refer to conference ID 61862496.
The archived conference call will be available on Five Prime's website beginning approximately two hours after the event and will be archived and available for replay for at least 30 days after the event.
About Five Prime
Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to improve the lives of patients with serious diseases. Five Prime's comprehensive discovery platform, which encompasses virtually every medically relevant extracellular protein, positions it to explore pathways in cancer, inflammation and their intersection in immuno-oncology, an area with significant therapeutic potential and a growing focus of the company's R&D activities. Five Prime has entered into strategic collaborations with leading global pharmaceutical companies and has promising product candidates in clinical and preclinical development. For more information, please visit www.fiveprime.com.
CONTACT: Heather Rowe Investor Relations 415-365-5737 [email protected]
